SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

WORK Medical Technology Group Ltd. engages in the development of health instruments. It manufactures and sells medical devices, including endotracheal tubes, laryngeal mask airways, heat and moisture exchanging filters, disposable breathing circuits, nebulizer kits, and yankauer suction sets. The company was founded on March 1, 2022 and is headquartered in Hangzhou, China.

Work Medical Technology Group Ltd - Ordinary Shares - Class A

Work Medical Technology Group Ltd

Work Medical Technology (WOK) is experiencing extreme volatility and intense trading volume after the company officially terminated its $200 million ATM equity offering agreement. The community is actively discussing the stock's massive intraday swings and parabolic moves, with many traders drawing comparisons to other high-momentum Chinese micro-cap runners and debating whether the surge represents a sustained squeeze or a classic pump-and-dump cycle.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is facing significant downward pressure as investors react to a $200 million common stock secondary offering that is being executed despite the company holding a substantial cash position. While the community remains deeply polarized between those betting on long-term growth from military drone contracts and those accusing management of predatory dilution, the stock is trending as shareholders demand clarity on whether these funds will fuel a transformational acquisition or simply sustain operations.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending after reporting that its pivotal REGAL trial has reached 78 of 80 required events, bringing the company to the brink of a major topline data readout. Investors are actively debating the timing of the final data, the potential for an imminent short squeeze, and the possibility of a buyout by major pharmaceutical companies as the trial nears completion.

Robinhood Ventures Fund I invest in companies located in the United States. The fund focuses on a broad range of sectors and industries. It provides financing for early stage transactions.

Robinhood Ventures Fund I - Common shares of beneficial interest

Robinhood Ventures Fund I (RVI) is seeing significant retail interest and volatility as investors speculate on its portfolio potential, particularly regarding exposure to high-profile companies like OpenAI and Databricks. Community sentiment is divided between optimism for long-term growth and frustration over initial price performance, with active debates centered on how its valuation compares to other private-market closed-end funds.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is trending as investors speculate on a potential take-private bid from Nelson Peltz's Trian Fund Management, fueling expectations of a massive short squeeze due to the stock's elevated short interest. The community is actively debating the viability of a buyout, weighing potential premiums against current growth initiatives and historical stock performance.

Wolfspeed, Inc. is an innovator of wide bandgap semiconductors, focused on silicon carbide and gallium nitride (GaN) materials and devices for power and radiofrequency (RF) applications. Its product families include silicon carbide and GaN materials, power devices and RF devices, and its products are targeted for various applications such as electric vehicles, fast charging, 5G, renewable energy and storage, and aerospace and defense. The company was founded by Calvin H. Carter Jr., John W. Palmour, F. Neal Hunter, Eric Hunter, and John Edmond in 1987 and is headquartered in Durham, NC.

Wolfspeed Inc - Ordinary Shares (New)

Wolfspeed Inc

Wolfspeed is experiencing significant volatility and heavy trading volume as investors debate its path to profitability following a major restructuring and recent earnings miss. The community is sharply divided, with some actively trading based on a potential short squeeze, while others remain skeptical due to the company's high debt load and history of shareholder dilution.

Index Coop is a decentralized autonomous organization (DAO) that builds structured DeFi products and strategy tokens. Index Coop offers a suite of sector index products, leverage and inverse products, and yield-generating products. The product suite runs on Set Protocol, an audited, self-custodial DeFi tool that allows for the creation and management of Ethereum-based (or ERC-20) tokens. Changes to the DAO are voted on by the owners of a governance token called INDEX and then implemented by a team of developers. INDEX holders wield voting power on a 1:1 basis, meaning one token equals one vote.

Index Cooperative

Index Cooperative is generating community excitement as traders highlight its extremely low circulating supply and small market cap as catalysts for a potential explosive move. The community is actively discussing the platform's focus on leveraged DeFi yield products while calling for increased volume to trigger a significant breakout.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

The iShares Silver Trust is seeing heightened activity as the community discusses a potential momentum breakout fueled by industrial demand in sectors like AI and semiconductor manufacturing. Investors are closely tracking silver's performance relative to gold and debating whether the recent price surge represents a sustained shift or a volatile swing within a broader inflationary environment.

Fabric.AI, Inc. engages in digital asset treasury activities. It focuses on the acquisition and management of assets related to the stable coin ecosystem. The company was founded on May 19, 2016 and is headquartered in New York, NY.

Fabric.AI Inc.

Fabric.AI is currently trending as investors focus on its low-float profile and high short interest, which has fueled speculation of a potential short squeeze. Community sentiment is largely driven by excitement surrounding a reported development partnership with Kopin Corporation, with many traders discussing the stock's role in the AI data center infrastructure and optical interconnect sector.

Sony Group Corp. engages in the development, design, manufacture, and sale of electronic equipment, instruments, devices, game consoles, and software for consumers, professionals and industrial markets. It operates through the following segments: Game and Network Services, Music, Pictures, Entertainment Technology & Services, Imaging and Sensing Solutions, Financial Services, and Others. The Game and Network Services segment deals with gaming machines, software and network services. The Music segment produces and publishes music and provides image media platforms. The Pictures segment handles film production, television program creation, and media networks. The Home Entertainment and Sound segment offers LCD televisions, home audio, Blu-ray Disc players and recorders, and memory-based portable audio devices. The Imaging and Sensing Solutions segment includes the image sensors business. The Financial Services segment manages the life insurance and non-life insurance operations and banking business. The Others segment consists of various operating activities, including the disc manufacturing and recording media businesses. The company was founded by Akio Morita and Masaru Ibuka on May 7, 1946 and is headquartered in Tokyo, Japan.

Sony Group Corporation - ADR

Sony Group Corporation

Sony is seeing heavy bullish sentiment as traders pile into call sweeps and options activity, reflecting significant anticipation for upside momentum. While the core gaming and entertainment segments remain a focal point for the community, recent price action is being fueled by strong investor confidence in the company's valuation and ongoing strategic initiatives.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Savara Reports First Quarter Financial Results and Provides Business Update

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2026 and...

Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will participate in a...

Savara (SVRA) to Release Earnings on Tuesday

Savara (NASDAQ:SVRA) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at...

Savara (NASDAQ:SVRA) Coverage Initiated by Analysts at Oppenheimer

Oppenheimer started coverage on Savara in a report on Friday. They issued an "outperform" rating and a $11.00 price target for the company...

FY2026 EPS Estimates for Savara Decreased by Lifesci Capital

Savara Inc. (NASDAQ:SVRA - Free Report) - Lifesci Capital cut their FY2026 EPS estimates for shares of Savara in a research report issued on Thursday, April 16th. Lifesci Capital analyst F. Brisebois...

Savara (NASDAQ:SVRA) Stock Price Up 2.5% - Here's Why

Savara (NASDAQ:SVRA) Trading Up 2.5% - Here's What Happened...

Savara Announces New Employment Inducement Grant

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. On April 14, 2026, the...

<ul class="summary-bullets"><li>The company was looking for FDA’s greenlight for molgramostim in Autoimmune Pulmonary Alveolar Proteinosis.</li><li>The company had submitted certain responses to the FDA recently which the agency determined represents a major amendment to the application, the company explained.</li><li>Savara added that the agency did not cite any safety, efficacy, or manufacturing concerns in their correspondence.</li></ul>Shares of Savara Inc. (SVRA) slumped as much as 4% after-hours on Wednesday after the company said that the U.S. Food and Drug Administration has extended the review time of its application seeking approval for its experimental therapy molgramostim by three months.The company was looking for the FDA’s greenlight for molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP), a rare lung disease where autoantibodies block the clearing of surfactant in the lungs, causing a buildup that disrupts oxygen exchange, creating breathing difficulties, and chronic coughing.The agency is now slated to decide on the application by November 22, Savara said. The former deadline for a decision was August 22.<h2 class="st-heading-2">Why The Delay?</h2>The company had submitted certain responses to the FDA recently, which the agency determined represents a major amendment to the application, the company explained. The additional time will allow the agency time to review the extra materials submitted, it added.Savara added that the agency did not cite any safety, efficacy, or manufacturing concerns in its correspondence.Savara completed submission of its application to the FDA for molgramostim as a treatment for aPAP in March. It was granted priority review by the agency. &nbsp;According to Savara, molgramostim has the potential to be the first and only approved therapy for Autoimmune PAP.The company had previously submitted an application for the experimental therapy but received a “refuse to file” letter from the FDA in May 2025 due to insufficient Chemistry, Manufacturing, and Controls data. The company resubmitted the application, stating that Fujifilm Biotechnologies will manufacture the drug substance. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SVRA stock stayed within the ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels.<a href="https://stocktwits.com/symbol/SVRA">SVRA stock</a> has more than doubled over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tsla-stock-on-track-for-best-day-in-nearly-seven-months-ahead-of-q1-earnings/cZJtNmERIwY">TSLA Stock On Track For Best Day In Nearly 7 Months Ahead Of Q1 Earnings As Musk Hails AI5 Milestone</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

SVRA Stock Slips Post-Market After FDA Delays Decision On Pulmonary Therapy

Savara Inc. (SVRA) was looking for FDA’s greenlight for molgramostim in Autoimmune Pulmonary Alveolar Proteinosis.

Equity

The agency is now slated to decide on the application by November 22, Savara said.


Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the FDA has extended the review period for the...

Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations at the ATS...

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.

Current Price	$5.08
Prev Close	$5.12
Open	$5.14
Dividend Yield	0.00%
50-Day Moving Average	$5.36
Beta	1.10
Avg. Volume	1.28M
PE Ratio	-9.51

52-Week High	$7.01
52-Week Low	$1.89
Market Capitalization	$1.05B
EPS (Annual)	-$0.5344
Price to Book	5.12
Revenue Per Employee	$0.00

SVRA
Savara Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SVRA News

SVRASavara Inc